Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg; Drug
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Atherosclerosis, Kidney Failure
Interventions: tacrolimus, mycophenolate mofetil, prednisone, sirolimus; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glioblastoma Multiforme
Interventions: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine; Drug · Radiation · Device
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Bacterial Conjunctivitis
Interventions: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Month and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 13 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more

Conditions: Solid Tumor, Pancreatic Adenocarcinoma
Interventions: OBI-3424; Drug
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • New Brunswick, New Jersey + 2 more

Conditions: Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
Interventions: Irinotecan (Camptosar), Gefitinib (Iressa); Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Dry Eye Disease
Interventions: sodium hyaluronate, vehicle; Drug
Lead sponsor: Lantibio; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Boynton Beach, Florida • Miami, Florida • Stuart, Florida + 6 more

Conditions: Herpes Simplex
Interventions: Valaciclovir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 10
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Lumbar Spondylolisthesis, Degenerative Disc Disease, Degenerative Spondylolisthesis, Lumbar Radiculopathy, Lumbar Spinal Stenosis, Lumbar Disc Disease
Interventions: ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system, Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system; Combination Product
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Healthy Volunteers
Interventions: ABBV-668 IR, ABBV-668 ER; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Inherited Immune Deficiencies
Interventions: Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG), Total Body Irradiation (TBI), Sirolimus or equivalent based on response; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Puberty, Precocious
Interventions: Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg; Drug
Lead sponsor: Abbott; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 21
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 16 more

Conditions: Neoplasms
Interventions: RO5503781, posaconazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Dallas, Texas

Conditions: Coronary Stenosis
Interventions: TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more

Conditions: Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Interventions: Luitpold Azacitidine, Vidaza®; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases
Interventions: SYNERGY XLV (Megatron) Coronary Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: New Haven, Connecticut • Clearwater, Florida • Boston, Massachusetts + 5 more

Conditions: Total Hip Arthroplasty
Interventions: Fish Oil; Dietary Supplement
Lead sponsor: Jeffrey L Stimac MD; Other
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Rheumatoid Arthritis
Interventions: Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control; Drug
Lead sponsor: Oryn Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Los Angeles, California • Tustin, California • Miami, Florida

Conditions: Healthy
Interventions: Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/500, CANA/MET XR FDC, Formulation 2, 150 mg/500 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions: Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: In-Stent Restenosis
Interventions: AGENT DCB 40 mm; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Tucson, Arizona • Los Angeles, California • Atlanta, Georgia + 8 more

Conditions: Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions: Varespladib, Placebo; Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Ventura, California • Miami, Florida • Munster, Indiana + 3 more

Search by objective public record fields.

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

AL-15469A for the Treatment of Bacterial Conjunctivitis

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System

Fish Oil in Total Hip Replacement Randomized Clinical Trial

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort

Study of Varespladib in Patients Hospitalized With Severe COVID-19